Become shareholders

Become shareholders

by | Jun 12, 2017 | Investors

Medesis Pharma is planning an introduction to the stock market in the years 2018/2019. Capital increases are made each year to finance all research and development. To invest in the capital of our company, please use the contact section of the site
Financing history: an atypical financing of the company

Financing history: an atypical financing of the company

by | Jun 12, 2017 | Investors

All capital contributions were exclusively made by private individuals. The company currently has 190 shareholders. We are mainly relying on capital infusions from our shareholders with a cumulated amount of €21 million injected in the Company capital over the last 14...
Treatment of Huntington’s disease

Treatment of Huntington’s disease

by | Jun 12, 2017 | Clinical stage products, Research

Huntington’s disease (HD) is a dominantly inherited neurodegenerative disease due to CAG expansion in the huntingtin gene. Through a screening on polyQ-hHTT aggregation in HeLa cells, F. Maschat (CNRS Montpellier) recently identified an inhibitory 23aa peptide (P42)...
Protection of healthy tissues in cancer radiotherapy

Protection of healthy tissues in cancer radiotherapy

by | Jun 12, 2017 | Research

Many patients suffer adverse effects from radiation therapy. These side effects may be acute, occurring during or within a few weeks after therapy, or intermediate to late, occurring months to years after therapy. This risk is higher in younger patients in part...
Personalized treatment of cancers

Personalized treatment of cancers

by | Jun 12, 2017 | Preclinical stage product

The use of AONYS®-API microemulsions will allow effective delivery of APIs targeting specific genes or proteins in tumors, resulting in tumor growth inhibition and shrinkage. Once the therapeutic potential of the Aonys®-API combination has been validated in the mouse...